BAMCO Inc’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

BAMCO Inc’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-197,980	Closed	-$27.3M	–	433
2021 Q4	$27.3M	Buy	197,980 +85,463	+76%	+$10.9M	0.06%	230
2021 Q3	$15.6M	Sell	112,517 -33,483	-23%	-$4.18M	0.04%	275
2021 Q2	$14.2M	Hold	146,000	–	–	0.03%	277
2021 Q1	$9.98M	Sell	146,000 -12,675	-8%	-$1.03M	0.02%	289
2020 Q4	$13.6M	Buy	158,675 +4,400	+3%	+$373K	0.03%	257
2020 Q3	$10M	Buy	154,275 +2,900	+2%	+$190K	0.03%	247
2020 Q2	$11.1M	Hold	151,375	–	–	0.04%	218
2020 Q1	$5.15M	Buy	151,375 +147,075	+3,420%	+$6.72M	0.03%	238
2019 Q4	$234K	Buy	+4,300	New	+$213K	﹤0.01%	314

Other funds holding BHVN

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

BAMCO Inc's BHVN Position: Q1 2022 in Review

BAMCO Inc sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q1 2022, closing a stake of 197,980 shares — an estimated $27.3M sold.

BAMCO Inc first reported a position in BHVN in Q4 2019 and held it in 9 quarters. The position peaked at $27.3M in Q4 2021. 307 funds tracked by Wall St. Rank hold BHVN as of Q1 2022.

BAMCO Inc reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q1 2022 after selling out during the quarter.
BAMCO Inc sold 197,980 Biohaven Pharmaceutical Holding Company Ltd. shares in Q1 2022, an estimated $27.3M.
BAMCO Inc first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2019 and held it in 9 quarters.
BAMCO Inc's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $27.3M in Q4 2021.
307 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q1 2022.

Based on BAMCO Inc's 13F filing for Q1 2022, filed 13 May 2022.